Who owns Nasus Pharma Ltd?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of NSRX from SEC Form 13F filings across 10 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 10 institutions disclosed 2.2M shares of Nasus Pharma Ltd worth $7.5M — about 26.8% of shares outstanding; the largest disclosed holder is Balyasny Asset Management L.P.. Source: SEC Form 13F filings, parsed by EvidInvest.
10
13F holders
$7.5M
value, 2026 filers
26.8%
of shares outstanding (2.2M sh)
4
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of NSRX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Balyasny Asset Management L.P. | 898,473 | $3.1M | 0.0% | 11.2% | 0.0% |
| 2 | Cable Car Capital, LP | 616,081 | $2.2M | 0.0% | 7.7% | +2.3% |
| 3 | Velan Capital Investment Management LP | 359,390 | $1.3M | 0.8% | 4.5% | 0.0% |
| 4 | Hudson Bay Capital Management LP | 134,771 | $471,699 | 0.0% | 1.7% | 0.0% |
| 5 | Bleichroeder LP | 89,848 | $314,468 | 0.1% | 1.1% | 0.0% |
| 6 | CITADEL ADVISORS LLCNEW | 22,004 | $77,014 | 0.0% | 0.3% | new |
| 7 | XTX Topco LtdNEW | 16,640 | $58,240 | 0.0% | 0.2% | new |
| 8 | RENAISSANCE TECHNOLOGIES LLCNEW | 12,200 | $42,700 | 0.0% | 0.2% | new |
| 9 | MORGAN STANLEY | 1,000 | $3,500 | 0.0% | 0% | -50.0% |
| 10 | Caitong International Asset Management Co., LtdNEW | 4 | $14 | 0.0% | 0% | new |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.